[go: up one dir, main page]

WO1999063992A8 - Novel calcium channel drugs and uses - Google Patents

Novel calcium channel drugs and uses

Info

Publication number
WO1999063992A8
WO1999063992A8 PCT/US1999/012672 US9912672W WO9963992A8 WO 1999063992 A8 WO1999063992 A8 WO 1999063992A8 US 9912672 W US9912672 W US 9912672W WO 9963992 A8 WO9963992 A8 WO 9963992A8
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
novel calcium
channel drugs
drugs
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/012672
Other languages
French (fr)
Other versions
WO1999063992A9 (en
WO1999063992A1 (en
Inventor
Yu-Hua Ji
Maya Natarajan
John H Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Priority to EP99928427A priority Critical patent/EP1085863A4/en
Priority to AU45493/99A priority patent/AU4549399A/en
Priority to CA002318901A priority patent/CA2318901A1/en
Priority to JP2000553061A priority patent/JP2002517440A/en
Publication of WO1999063992A1 publication Critical patent/WO1999063992A1/en
Anticipated expiration legal-status Critical
Publication of WO1999063992A8 publication Critical patent/WO1999063992A8/en
Publication of WO1999063992A9 publication Critical patent/WO1999063992A9/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Novel multibinding compounds are disclosed. The compounds of this invention comprise 2 - 10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca++ channel, thereby modulating the biological activities thereof.
PCT/US1999/012672 1998-06-08 1999-06-07 Novel calcium channel drugs and uses Ceased WO1999063992A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99928427A EP1085863A4 (en) 1998-06-08 1999-06-07 Cross-reference to related applications
AU45493/99A AU4549399A (en) 1998-06-08 1999-06-07 Novel calcium channel drugs and uses
CA002318901A CA2318901A1 (en) 1998-06-08 1999-06-07 Novel calcium channel drugs and uses
JP2000553061A JP2002517440A (en) 1998-06-08 1999-06-07 New calcium channel drugs and uses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US60/088,465 1998-06-08
US9306898P 1998-07-16 1998-07-16
US60/093,068 1998-07-16
US10386698P 1998-10-12 1998-10-12
US60/103,866 1998-10-12

Publications (3)

Publication Number Publication Date
WO1999063992A1 WO1999063992A1 (en) 1999-12-16
WO1999063992A8 true WO1999063992A8 (en) 2001-02-22
WO1999063992A9 WO1999063992A9 (en) 2002-08-22

Family

ID=27375969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012672 Ceased WO1999063992A1 (en) 1998-06-08 1999-06-07 Novel calcium channel drugs and uses

Country Status (7)

Country Link
EP (1) EP1085863A4 (en)
JP (1) JP2002517440A (en)
AR (1) AR020876A1 (en)
AU (1) AU4549399A (en)
CA (1) CA2318901A1 (en)
SG (1) SG80038A1 (en)
WO (1) WO1999063992A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
ATE437641T1 (en) 2003-05-15 2009-08-15 Roskamp Res Llc METHOD FOR PRODUCING MEDICATIONS FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY AND MICROGLIOSIS
ES2449594T3 (en) 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Method to reduce amyloid deposition, amyloid neurotoxicity and microgliosis with enantiomer (-) - nilvadipine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042769A1 (en) * 1980-11-13 1982-06-09 Bayer Ag, 5090 Leverkusen C-3 LINKED 1,4-DIHYDROPYRIDINE, THEIR USE IN MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
KR100517210B1 (en) * 1994-12-12 2006-06-07 오메로스 코포레이션 Infusion solution for pain, inflammation and spasm
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor

Also Published As

Publication number Publication date
JP2002517440A (en) 2002-06-18
SG80038A1 (en) 2001-04-17
EP1085863A1 (en) 2001-03-28
WO1999063992A9 (en) 2002-08-22
AR020876A1 (en) 2002-06-05
AU4549399A (en) 1999-12-30
EP1085863A4 (en) 2001-03-28
CA2318901A1 (en) 1999-12-16
WO1999063992A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
ZA9710098B (en) Halogenopyrimidines.
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2000031124A3 (en) Peptides that modulate the interaction of b class ephrins and pdz domains
WO1999063944A3 (en) Novel therapeutic agents that modulate estrogen receptors
WO2001068142A9 (en) Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
WO1999011791A3 (en) Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DE69634909D1 (en) Luminescent lanthanide chelates labeled biospecific binding reactants and their use
HUP0003921A3 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
WO2003050295A3 (en) Assays and implements for determining and modulating hsp90 binding activity
IS5888A (en) Chemotherapy for Acetyldinalin Mixed Gemsitabine, Capesitabine or Cisplatin
DE69802615D1 (en) Triaromatic compounds, compositions containing them and their uses
ZA98533B (en) Soluble CTLA4 mutant molecules and uses thereof.
DE69807435D1 (en) Mixer for mixing paints, dyes or the like.
AU2682499A (en) Anion binding polymers and the use thereof
WO1999032509A3 (en) Hemiasterlin analogs
DK1049721T3 (en) Synthetic polysaccharides, processes for their preparation and pharmaceutical compositions containing them
GB0109957D0 (en) Binding system
WO1999064040A8 (en) Novel polyene macrolide compounds and uses
WO1999063992A8 (en) Novel calcium channel drugs and uses
WO2001012664A3 (en) Notch receptor ligands and uses thereof
AU2001291771A1 (en) Cycloaliphatic/aromatic diphosphines and use thereof in catalysis
AU1724300A (en) Calcium binding protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999928427

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref document number: 2318901

Country of ref document: CA

Ref country code: CA

Ref document number: 2318901

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 505978

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 45493/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000/04563

Country of ref document: ZA

Ref document number: 200004563

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 09674422

Country of ref document: US

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 553061

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWP Wipo information: published in national office

Ref document number: 1999928427

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 61-66 AND 126-131, DESCRIPTION, REPLACED BY NEW PAGES 61A-66 AND 126-131; PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999928427

Country of ref document: EP